Swiss Venture Capital Report

2024 – Dynamic stagnation





Authors




Stefan Kyora Editor in Chief at Startupticker.ch stefan.kyora@jnb.ch Tel. 076 325 99 41



Thomas Heimann Deputy General Secretary at SECA thomas.heimann@seca.ch Tel. 079 709 02 96

At a glance

Amount: 8.5% decrease



 Invested capital on pre-pandemic level (2019)

First recorded downturn of funding rounds

The Top 20 Rounds

Strong biotech



Amount invested: 15% less than in the previous year


Biotech and cleantech dominant sectors

ICT and fintech weak

Start-up from 9 cantons

Swiss investors involved in 9 of the top 20 rounds

Cantons: amount




Diversity increases

- Zurich down: 27.1%
- Zug down: 47.3%
- Vaud up: 13.3%
- Geneva up: 81.3%
- All time records in Bern

Sectors

Deeptech sectors provided stability, while fintech start-ups struggled



Biotech (+50%) - 4 of 5 largest

financing rounds

Healthcare IT recovered from low

in 2023 (+226%)

Fintech (-52%) / ICT (-13%)


Cleantech (-25%) without larger

round(s)

Micro/Nano achieved same level

Sectors

Healthcare IT, Biotech and Cleantech on the Rise



Highest jump for Health IT (+23%)


Biotech / Cleantech (+20% / +10%)

Medtech (-21%) - multi-year growth trend still intact

Post-pandemic fatigue in tech sectors continued (Fintech -32%; ICT: -19%)

Phases


Volume in Later Stage Rounds Against the Trend



Decline in number of rounds (Later: -15%; Early: -6%; Seed: -11%) Later stage money invested: -1%; Early: -20%; Seed: -19% ICT early stage volume (+91%) - 8 rounds above 10 million (vs. 1 in 2023) **Broad weakness in Fintech (later** stage volume: -62%; early -39%)

Phases

Lowest concentration among Top rounds / Strong increase in median



Amount known for 258 (out of 357) financing rounds (72% of total)

Share Top 3: 14% (22/23: 35/20%) Share Top 20: 49% (22/23: 65/55%) Median of rounds at 3m (+41%) later +91% (12.0m); early +78% (4.3m), seed unchanged (1.4m)

30 rounds above 20m (2014/19: 7/19)


Cleantech involved in 7 of the Top 20

1 ICT and 1 fintech in Top 20 (24: 5/2)

Phases


Declining Growth Rates Over Mid-Term

Annualised growth rate




Phases / Sectors

10+ million Rounds in ICT on the Rise – Fintech Quite The Opposite




Phases / Sectors

Larger Rounds in Biotech and Health IT




Healthcare IT rounds - Year over year growth; n: 63



Venture Capital Funds


Vibrant Activity in Fundraising - 46 Open Funds with 25 First Closings




For illustrative purposes only – full details can be found in the SVCR 2025; some managers have more than one fund in the offering and have a specific focus on the respective development stage (f.ex. pre-seed, pre-series A, early B, etc.). Source: according to SVCR Investor Survey Dec 2024 (100 answers; survey sent to 300+ contacts).

Critical Fund Size Not Yet Reached – Young Industry

Current fee-paying assets



Founding Year of the VC Manager; n=63



in Mio. CHF

Source: according to SVCR Investor Survey Dec 2024 (100 answers; survey sent to 300+ contacts); only still active managers; Corporate VCs not considered in the above statistics

Brightening Mood Among Swiss VC Managers

More optimistic about fundraising, valuations and exits

63% of VCs state that market conditions have affected their fundraising – structural deficits remain


76% expect a higher investment volume in Switzerland in the next 12 months

62% expect rising valuations and 68% expect more exits

64% intend to increase their involvement in Swiss start-ups


Exit is the Name of the Game

Most relevant reasons for exit reluctancy (multiple responses possible); n=76




Source: according to SVCR Investor Survey Dec 2024 (100 answers; survey sent to 300+ contacts); only still active managers; Corporate VCs not considered in the above statistics

Exit opportunities over the next 12 months (compared to last 12 months); n=76




Growing Confidence in Valuation and Outlook



Source: according to SVCR Investor Survey Dec 2024 (100 answers; survey sent to 300+ contacts); only still active managers; Corporate VCs not considered in the above statistics

Exit

Sluggish business



- Exits remain on low level
- No IPO recorded in 2024
- Swiss buyers cautious
- Highlights
- BETA CAE Systems Cadence
- Calypso Biotech Novartis
- FemtoTools Oxford
- Sevensense ABB

Conclusion

- High share of foreign funding
 - > Stabilizing factor
- Capital-intensive deep tech start-ups
 - > Attracting investors in crisis too
- Weakness in growth capital
 - > scale-ups find money, mega rounds missing
- Few and small exits
 - > No IPOs, few Swiss acquirers, some larger exits

Partners

A collective endeavour



Enjoy your reading...

- Thanks to partners and sponsors
- Print-Version
- PDF-Version with links to details Website: <u>www.startupticker.ch</u> under «Assets»

Contact persons: Stefan Kyora, startupticker.ch: stefan.kyora@jnb.ch, Tel. 041 226 20 80 Thomas Heimann, SECA: thomas.heimann@seca.ch, Tel. 079 709 02 96



Panel discussion

Maria Anselmi, Head of Start-ups and Next-Generation Innovators Division

Jordi Montserrat, Co-Managing Director Venture Kick

Joanne Sieber, CEO Deep Tech Nation Switzerland Foundation


Stefan Steiner, Startup.ch, Co-Managing Director Venturelab

Pascale Vonmont, President Startupticker Foundation

Appendix

European perspective

Similar trends




- 2024 invested amount Europe: EUR 56.7 billion
- 2024 number of rounds Europe: 9'600


Source: PitchBook, Swiss Venture Capital Report 2025

European perspective

High number of start-ups

Number of funding rounds (index 2014 = 100)






Source: PitchBook, Swiss Venture Capital Report 2025

European perspective

Exit hype vs. Investment hype



Source: PitchBook, Swiss Venture Capital Report 2025


 Exit hype during pandemic

 2023 / 24 above precovid level

Phases / Sectors

ICT & Fintech Rounds Overall Decline With A Bright Spot


Year over year growth; n: 534




Phases / Sectors

Strong Development in Biotech & Recovery in Health IT

Year over year growth; n: 247




Cleantech and Micro/Nano Against the Trend



Gap between CHF 10-20 million Less Accentuated

Percentage of rounds; n= 2,097



9% of rounds between 10 and 20 million

80

70

60

50

40

30

20


10

Π

Seed

Seed/Early & Small is Beautiful

Development Stage Focus of VC investors; n: 211 (multiple responses possible)




Source: according to SVCR Investor Survey Dec 2024 (100 answers; survey sent to 300+ contacts); only still active managers; Corporate VCs not considered in the above statistics

C)

Higher Allocation in Swiss-based Startups Expected


Number of New Investments (expected) in Swiss-Based Startups



Source: according to SVCR Investor Survey Dec 2024 (100 answers; survey sent to 300+ contacts); only still active managers; Corporate VCs not considered in the above statistics

Exit Strategies Among Limited Partners' Top Preference

Highest topics of LP pressure (n: 27) (multiple responses possible)



Source: according to SVCR Investor Survey Dec 2024 (100 answers; survey sent to 300+ contacts); only still active managers; Corporate VCs not considered in the above statistics